Actually, conventional interventions and treatment strategies based on the single or combined use of chemical and biochemical antihyperglycemic and hypoglycemic agents, e.g., thiazolidinediones, sulphonylureas, metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-IV) enzyme inhibitors, insulin, or glucagon-like peptide-1 (GLP-1) agonists are the mainstay of diabetes management [7]. The gene discussed is SLC5A2; the disease is diabetes mellitus.